1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2016
-
Mark
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
(
- Contribution to journal › Article
- 2015
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article